Detalhe da pesquisa
1.
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
N Engl J Med
; 379(18): 1711-1721, 2018 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30380386
2.
Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and ratesâ©.
Int J Clin Pharmacol Ther
; 55(7): 606-620, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28590244
3.
A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback.
J Math Biol
; 75(1): 33-84, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27832321
4.
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.
Br J Clin Pharmacol
; 80(6): 1337-49, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26182954
5.
At the bench: the key role of PK-PD modelling in enabling the early discovery of biologic therapies.
Br J Clin Pharmacol
; 77(5): 740-5, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23962236
6.
A mathematical analysis of rebound in a target-mediated drug disposition model: I.without feedback.
J Math Biol
; 68(6): 1453-78, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23591581
7.
Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency.
J Theor Biol
; 281(1): 113-21, 2011 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-21557949
8.
Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma.
J Clin Pharmacol
; 61(7): 901-912, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33368307
9.
Targeting macrophage checkpoint inhibitor SIRPα for anticancer therapy.
JCI Insight
; 5(12)2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32427583
10.
Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
Br J Clin Pharmacol
; 67(2): 153-60, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19076987
11.
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
J Clin Oncol
; 37(12): 946-953, 2019 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30811285
12.
A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilators.
Eur J Pharm Sci
; 34(4-5): 250-6, 2008 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-18547791
13.
Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma.
Clin Pharmacol Ther
; 103(5): 826-835, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28758192
14.
The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
Drug Discov Today
; 12(23-24): 1018-24, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18061880
15.
The application of mathematical modelling to the design of bispecific monoclonal antibodies.
MAbs
; 8(3): 585-92, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26910134
16.
Analytical assay platforms for soluble target engagement biomarkers: old favorites and emerging technologies.
Bioanalysis
; 5(23): 2919-31, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295118
17.
Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach.
BMC Syst Biol
; 6: 141, 2012 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23146124
18.
Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development.
Drug Discov Today
; 16(23-24): 1031-6, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22020181
19.
Inhalation by design: novel tertiary amine muscarinic M3 receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.
J Med Chem
; 54(19): 6888-904, 2011 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-21870878
20.
Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: Nonerythropoietin receptor-mediated pathways may play a major role.
J Pharm Sci
; 98(6): 2198-211, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18837016